ARTICLE | Distillery Therapeutics
HAS2 and NOTCH1 identified as targets in liver fibrosis induced by hepatitis B, hepatitis C and NASH
June 19, 2019 8:06 PM UTC
INDICATION: Liver fibrosis; non-alcoholic steatohepatitis (NASH)...
BCIQ Company Profiles